6-tert-butyl-N-{2-methyl-3-[8-(4-morpholin-4-ylmethyl-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-nicotinamide | 886854-82-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-tert-butyl-N-{2-methyl-3-[8-(4-morpholin-4-ylmethyl-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-nicotinamide
• 英文别名: 6-tert-butyl-N-[2-methyl-3-[8-[4-(morpholin-4-ylmethyl)anilino]imidazo[1,2-a]pyrazin-6-yl]phenyl]pyridine-3-carboxamide
• CAS: 886854-82-6
• 化学式: C₃₄H₃₇N₇O₂
• 分子量: 575.713
• InChiKey: MATAVMDLWVPDOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  96.7
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-溴-6-硝基甲苯 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 palladium 10% on activated carbon lithium aluminium tetrahydride 、 氢气 、 potassium acetate 、 sodium carbonate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙二醇二甲醚 、 异丁酰胺 、 乙酸乙酯 为溶剂， 95.0 ℃ 、275.8 kPa 条件下， 反应 39.58h， 生成 6-tert-butyl-N-{2-methyl-3-[8-(4-morpholin-4-ylmethyl-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-nicotinamide
  参考文献：
  名称：

  WO2008/33858

  摘要：

  公开号：

文献信息

• Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
  申请人：Currie S. Kevin

  公开号：US20060178367A1

  公开（公告）日：2006-08-10

  Chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are described herein. Pharmaceutical compositions comprising at least one chemical entity of Formula 1, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell proliferation are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了从1号式化合物中选择的化学实体及其药学上可接受的盐、溶剂化物、晶体形式、螯合物、非共价复合物、前药和混合物。本文还描述了包含1号式化学实体至少一种和至少一种药学上可接受的载体、辅料和赋形剂的制药组合物。本文还描述了治疗对Btk活性和/或B细胞增殖抑制有反应的某些疾病患者的方法。本文还描述了检测样品中Btk存在的方法。
• Certain substituted amides, method of making, and method of use thereof
  申请人：Brittelli R. David

  公开号：US20060229337A1

  公开（公告）日：2006-10-12

  At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了至少选择自公式2化合物和药学上可接受的盐、溶剂化合物、螯合物、非共价复合物、前药和其混合物中的至少一种化学实体。本文还描述了包括本发明中至少一种化学实体以及至少一种药学上可接受的载体、佐剂和赋形剂在内的制药组合物。本文还描述了治疗对Btk活性和/或B细胞活性抑制有反应的某些疾病的患者的方法。本文还描述了用于确定样品中Btk存在的方法。
• Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
  申请人：Whitney James A.

  公开号：US20100160292A1

  公开（公告）日：2010-06-24

  Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.

  提供通过抑制BTK Y551的磷酸化来抑制BTK活性的方法，提供通过抑制BTK Y551的磷酸化来治疗患者的方法，提供结合BTK并抑制复合物的化学实体。
• Kinase inhibitors, and methods of using and identifying kinase inhibitors
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP2270200A2

  公开（公告）日：2011-01-05

  A method of identifying a chemical entity that inhibits BTK by inhibiting phosphorylation of Y551, methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation ofY551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.

  提供了一种通过抑制 Y551 磷酸化来抑制 BTK 的化学实体的鉴定方法、通过抑制 BTK 的 Y551 磷酸化来抑制 BTK 活性的方法、通过抑制 BTK 的 Y551 磷酸化来抑制 BTK 活性从而治疗患者的方法、与 BTK 结合的化学实体以及被抑制的复合物。
• IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP1812442A2

  公开（公告）日：2007-08-01